RocRock Bio-technology (Shenzhen) Co., Ltd. ("RocRock Bio") and Suzhou Pu-Heng Technology Co., Ltd. ("Pu-Heng Technology") have entered into a strategic cooperation agreement. They will jointly use the 3D NAC-Organ technology platform to develop a high-throughput in vitro screening system for CAR-Macrophage cells, to speed up the research and development of new immunotherapies for solid tumors.
Every year, nearly 20 million new cancer cases are diagnosed globally, with solid tumors like lung, liver, and stomach cancer being common in China. As the population ages, cancer treatment and care are becoming major healthcare challenges.
For end - stage cancer patients, tumor immunotherapy is a key treatment. CAR-T cell therapy works well for blood - related cancers but is less effective for solid tumors. Macrophages, which can infiltrate and kill tumors, are being genetically modified to improve their tumor - targeting ability. These modified CAR-Macrophages (CAR-M) have shown strong tumor - specific phagocytosis and clearance in tests, suggesting they might work for immune "cold" tumors.
traditionally used mice for assessment. But due to differences between mice and humans, many drugs, especially antibody - based immunotherapies, don't work in humans as they do in mice. The development of in vitro human - based 3D disease models offers a better tool for anti - tumor drug research. In late 2021, China's National Medical Products Administration (NMPA) recommended using in vitro 3D models for evaluating cell therapy products. In 2022, the U.S. FDA was allowed to accept new drug applications without requiring animal testing, encouraging the use of human - based in vitro models. These changes promote the use of in vitro 3D models in drug research.
Good 3D solid tumor models can speed up CAR-M development. On November 18, 2022, RocRock Bio and Pu-Heng Technology signed a strategic cooperation agreement in Suzhou. They will jointly build a high-throughput in vitro screening system for CAR-M using Pu-Heng's NAC-Solid Tumor platform. This platform creates 3D solid tumor models with immune cells, helping assess tumor targeting, infiltration, and killing, and supporting CAR-M immunotherapy development.
RocRock Bio stated that Pu-Heng's NAC-Solid Tumor platform offers efficient efficacy assessment for their CAR-M research, accelerating pipeline development and keeping their technological edge in macrophage - targeted solid tumor treatment.
Pu-Heng Technology expressed its pleasure in collaborating with RocRock Bio, a leader in CAR-M development. This partnership will leverage each other's technical strengths to build an advanced cell therapy R & D platform. It will also speed up Pu-Heng Technology's development in cell therapy assessment platforms, helping achieve its strategic goal of creating a comprehensive efficacy evaluation platform for various biological technology innovation drugs, including cell and gene therapies.
The NAC-Solid Tumor system evaluates CAR-M efficacy by establishing a model with SKOV3 cells. After 48 hours, Macrophage and CAR-M cells are added in proportion. The system observes tumor microsphere morphology, analyzes Macrophage infiltration, and assesses SKOV3 3D NAC-Organ damage through LDH and ATP tests.
图一，CAR-Macrophage细胞对实体瘤靶向能力评估。将GFP标记的Macrophage/CAR-M细胞加入3D 肿瘤NAC-organ 48h后，发现95%的CAR-M细胞侵入到实体瘤模型中，说明CAR修饰的Macrophage对于实体肿瘤有较强的靶向能力。 通过对细胞活力（ATP）和细胞损伤（LDH）的检测，相较于Macrophage，CAR-Macrophage对3D NAC-Organ有更强的杀伤能力。
Free AI Website Maker